Q4 FY 2026. Management view "We capped off a year of consistent execution across the business with a strong fourth quarter. Full-year ...

Good morning and welcome to the AngioDynamics Fiscal Year 2026 Fourth Quarter and Full Year Earnings Call. [Operator Instructions]. As a reminder, this conference call is being recorded. The news ...

Key Points Interested in AngioDynamics, Inc.? Here are five stocks we like better. Revenue growth was led by med tech: AngioDynamics reported Q4 revenue up 8% to $86.6 million and full-year ...

The optimal endovascular management of cervical carotid dissection causing tandem occlusion remains uncertain. We investigated the impact of emergent carotid stenting during endovascular treatment for ...